Immunis, Inc.
PrivateLast Round
Seed Round
May 28, 2026
Est. Valuation
$30M
Total Funding Raised
$35.25M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Immunis, Inc. operates in Healthcare & Life Sciences and is based in Irvine, California. Its latest recorded funding round was a Grant round in May 2025.
Immunis, Inc. is a biotechnology company that develops multi-active biologics derived from stem cell secretomes to address age-related diseases and immune dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunis, Inc. Comparables
Compare Immunis, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Secretome Therapeutics | 84% | |
| MyoPax | 77% | |
| Remedy Cell Ltd. | 76% |
For institutional investors. Book with your work email.
Immunis, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | May 28, 2026 | ||||
| Grant | May 12, 2025 | ||||
| Series A Extension | Jan 11, 2025 | ||||
| Series A | Aug 3, 2022 |
For institutional investors. Book with your work email.
Immunis, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Remiges Ventures | Series A Extension, Series A |
| BOLD Capital Partners | Series A Extension |
| X PRIZE Foundation | Grant |
| Continuum Health Ventures | Series A Extension, Series A |
| LifeSpan Vision Ventures | Series A Extension |
| JLS Fund | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2026
Named Top Biotech and Life Sciences Company of 2026.
- Jul 25, 2026
Monthly visitors increased 34% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 10, 2026
Immunis, Inc., a clinical-stage biotechnology company, is developing novel multi-active biologics, including lead investigational therapy IMM01-STEM, to address age-related muscle and metabolic decline.
- attends_eventNov 10, 2026
Immunis, Inc.'s Chief Science Officer, Dr. Tom Lane, presents new preclinical data on the investigational IMM01-STEM therapy at Obesity Week in District of Columbia in Nov '26.
- recognized_asNov 10, 2026
The National Academy of Medicine recognizes Immunis, Inc. as the Healthy Longevity Global Competition Grand Prize recipient in October 2026, following the company’s second year on The Healthcare Technology Report’s Top Biotech and Life Sciences Companies of 2026 list.
- recognized_asNov 10, 2026
Immunis, Inc. is named one of The Healthcare Technology Report’s Top Biotech and Life Sciences Companies of 2026, recognizing it among companies advancing promising medical innovations, in California on Nov 10th ’26.
- is_developingOct 21, 2026
As of Oct 21st '26, Immunis, Inc. is developing IMM01-STEM, a multi-pathway biologic in a randomized Phase 2 clinical trial, to help preserve strength, mobility, and metabolic health as people age.
For institutional investors. Book with your work email.
Immunis, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immunis, Inc.'s valuation, stock price, and market status.
Is Immunis, Inc. a public or private company?
Immunis, Inc. is a private company.
What is the current stock price of Immunis, Inc.?
Immunis, Inc. is a private company, so its shares have no public market price. Caplight tracks Immunis, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immunis, Inc. worth (valuation)?
Immunis, Inc.'s valuation is estimated at $30.0M based on funding round data.
Can I buy Immunis, Inc. stock?
Immunis, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immunis, Inc.'s last funding round?
Immunis, Inc.'s most recent funding round was Seed Round on May 28, 2026.
Who are the main investors in Immunis, Inc.?
Key investors in Immunis, Inc. include Remiges Ventures.
Will Immunis, Inc. IPO soon?
No public IPO plans have been announced for Immunis, Inc..
How can I track Immunis, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Immunis, Inc.'s shares on secondary markets.